Nautilus BiotechnolgyNAUT
Market Cap: $320M
About: Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. It has built a prototype of a single-molecule instrument, Proteomic Analysis System.
Employees: 164
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
600% more call options, than puts
Call options by funds: $7K | Put options by funds: $1K
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
15% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 20
5% more funds holding
Funds holding: 73 [Q1] → 77 (+4) [Q2]
0.21% more ownership
Funds ownership: 50.88% [Q1] → 51.09% (+0.21%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q1] → 3 (+0) [Q2]
20% less capital invested
Capital invested by funds: $187M [Q1] → $150M (-$37.4M) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Guggenheim Subbu Nambi 50% 1-year accuracy 5 / 10 met price target | 135%upside $6 | Buy Initiated | 27 Jun 2024 |